Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Oligonucleotide Enzyme Surrogate (OnES)

    SBC: Accacia International LLC            Topic: CBD08108

    Historically organophosphorus compounds such as insecticides and nerve agents have been susceptible to decomposition by proteinaceous enzymes. Organophosphate hydrolases (OPH) represent a practical method to deactivate such compounds peripherally and on surfaces. However, when such organophosphates are ingested, the use of proteinaceous enzymes such as OPH can be problematic because of their tende ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  2. Ribozymes for In Vivo Degradation of G-Nerve Agents

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08108

    Given the possibility to administer prophylactic doses of protein bioscavengers inactivating OP nerve agents before they reach their acetylcholinesterase target, much attention has been given to proteins such as human butyrylcholinesterase and paraoxonase I. As small nucleic acid catalysts can exhibit triphosphoesterase activities, the identification of new molecules active against nerve agents w ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  3. Collective Protection for Military Working Dogs

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08103

    Shelter enclosures for military working dogs in the event of a CB attack is a technology gap identified by the Joint Requirements Office. Important parameters to consider in the design of protective enclosures include low weight and size to minimize transport requirements; rapid setup; and accommodation of canine physiological and psychological comfort needs. The overall operational weight of th ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  4. Multiple Indication Adjuvants

    SBC: BIOPROTECTION SYSTEMS CORP.            Topic: CBD08105

    The objective of this study is to demonstrate the efficacy and broad applicability of the human immune-modulating alphaGal Adjuvant Technology for antiviral vaccine development. We will use viral vaccine candidates for the select Category A viral pathogens Zaire ebolavirus (ZEBOV, filovirus), Rift Valley fever virus (RVFV, bunyavirus), and Lassa virus (LV, arenavirus), to evaluate the adjuvant pot ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  5. Mass Customization Biomanufacturing Process

    SBC: Chesapeake Perl, Inc.            Topic: N/A

    "Chesapeake PERL, Inc aims to develop baculovirus-based expression in insect larvae from bench-scale to mass manufacturing. The technology platform consists of automated mass insect rearing, and inoculation combined with monitoring of protein expressionlevels in larvae via a fluorescent reporter. This allows the development of "mass customization" for recombinant protein manufacturing in insect ...

    SBIR Phase I 2002 Department of DefenseOffice for Chemical and Biological Defense
  6. Automated Preferential Display for the Analysis of Gene Expression Profiles

    SBC: GENEXPRESS INFORMATICS, INC.            Topic: N/A

    "GeneXpress Informatics, Inc. (GXI) and Dr. James P. Chambers of UTSA propose to develop a revolutionary differential gene display technology, called Preferential Display (PD) which will provide for a simplified, cost-effective method to identify thesegenes for use in discovering gene expression profiles without having any prior knowledge of an organism, tissue or biological samples' genome. The ...

    SBIR Phase I 2002 Department of DefenseOffice for Chemical and Biological Defense
  7. New DNA/RNA Sequencer for Rapid Assessment of Exposure to Infectious Agents

    SBC: Lynntech Inc.            Topic: N/A

    "The importance of DNA/RNA-based assays for detection of biological warfare agents, identification of diseases, genome sequencing, and environmental control is enormous and will inevitably increase. The challenge is the development of low cost andportable methods for sequencing DNA and RNA extracted from surfaces and fluids, to recognize exposure to biowarfare agents. All the conventional techn ...

    SBIR Phase I 2002 Department of DefenseOffice for Chemical and Biological Defense
  8. Blood Brain Barrier (BBB) Permeable Encapsulating Agents for Effective Delivery of CNS-active Agents

    SBC: Lynntech Inc.            Topic: CBD08107

    Drug transport in the central nervous system is highly regulated by the Blood-Brain Barrier (BBB). Most medicines, including many for treating cancer, Alzheimer’s, and stroke, do not meet essential criteria, such as lipophilicity and low molecular weight, required for appreciable transport into the brain. However, endogenous peptides, such as insulin or transferrin, and certain monoclonal anti ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  9. Sequential Isoelectric Point Separation of Proteins Using Non-Gel, Microfluidic System

    SBC: Lynntech Inc.            Topic: CBD08101

    The measurement of biochemical changes within the human body can provide a means to monitor a person’s physiological health. Many of the biochemicals that provide a snapshot of a person’s health are proteins. The challenge with measuring proteins is the existence of approximately ten orders of magnitude difference in concentration between the most abundant proteins in blood and those typically ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  10. MOEMS Miniaturized Real-time Visible/UV Spectrometer

    SBC: MORGAN RESEARCH CORP.            Topic: N/A

    "This Phase I SBIR proposal is for the initial development of a miniaturized real-time visible/UV spectrometer based on micro-opto-electro-mechanical systems (MOEMS) technology. Use of MOEMS technology enables orders of magnitude reductions in size, weightand power from the smallest spectrometers commercially available today and virtually assures exceeding stated corresponding SBIR requirements. ...

    SBIR Phase I 2002 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government